The disposition of valproyl glycinamide and valproyl glycine in rats

被引:15
作者
Blotnik, S
Bergman, F
Bialer, M
机构
[1] HEBREW UNIV JERUSALEM,SCH PHARM,FAC MED,DEPT PHARMACEUT,IL-91120 JERUSALEM,ISRAEL
[2] HEBREW UNIV JERUSALEM,SCH PHARM,FAC MED,DEPT PHARMACOL,IL-91120 JERUSALEM,ISRAEL
[3] HEBREW UNIV JERUSALEM,SCH PHARM,FAC MED,CTR PHARM,IL-91120 JERUSALEM,ISRAEL
关键词
valproyl glycinamide; valproyl glycine; pharmacokinetics; brain and liver distribution;
D O I
10.1023/A:1012143631873
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To investigate the disposition of valproyl glycinamide and valproyl glycine in rats and to compare it with that of valproic acid (VPA) and valpromide which were studied previously. Methods. The study was carried out by monitoring the brain and liver levels of valproyl glycinamide and valproyl glycine (as a function of time after iv dosing) in addition to the regular pharmacokinetic (PK) monitoring of plasma and urine levels of these compounds. Results. The following PK parameters were obtained for valproyl glycinamide and valproyl glycine, respectively: clearance, 7.1 and 16 ml/min/kg; volume of distribution (Vss), 0.78 and 0.41 l/kg; half-life, 1.1 and 0.37 h; and mean residence time, 1.8 and 0.4 h. The ratios of AUCs of valproyl glycinamide of liver to plasma and brain to plasma were 0.70 and 0.66, respectively. The ratios of the AUCs of valproyl glycine of liver to plasma and brain to plasma were 0.19 and 0.02, respectively. Conclusions, Valproyl glycinamide distributes better in the brain than VPA, a fact which may contribute to its better anticonvulsant activity. Valproyl glycine was barely distributed in the brain, a fact which may explain its lack of anticonvulsant activity. In addition to the liver, the brain was found to be a minor metabolic site of the biotransformation of valproyl glycinamide to valproyl glycine.
引用
收藏
页码:873 / 878
页数:6
相关论文
共 13 条
[1]  
ABUSALACH O, 1994, PHARMACEUT RES, V11, P1429
[2]  
Altman P. L., 1974, BIOL DATA BOOK, V3, P1702
[3]   NONCOMPARTMENTAL DETERMINATION OF THE STEADY-STATE VOLUME OF DISTRIBUTION [J].
BENET, LZ ;
GALEAZZI, RL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (08) :1071-1074
[4]   Progress report on new antiepileptic drugs: A summary of the Third Eilat Conference [J].
Bialer, M ;
Johannessen, SI ;
Kupferberg, HJ ;
Levy, RH ;
Loiseau, P ;
Perucca, E .
EPILEPSY RESEARCH, 1996, 25 (03) :299-319
[5]  
Blotnik S, 1996, DRUG METAB DISPOS, V24, P560
[6]  
Gibaldi M. P., 1982, PHARMACOKINETICS
[7]   PHARMACOKINETIC ANALYSIS AND ANTIEPILEPTIC ACTIVITY OF N-VALPROYL DERIVATIVES OF GABA AND GLYCINE [J].
HADAD, S ;
BIALER, M .
PHARMACEUTICAL RESEARCH, 1995, 12 (06) :905-910
[8]   UTILIZATION OF AREA UNDER CURVE TO ELUCIDATE DISPOSITION OF AN EXTENSIVELY BIOTRANSFORMED DRUG [J].
KAPLAN, SA ;
JACK, ML ;
COTLER, S ;
ALEXANDER, K .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1973, 1 (03) :201-216
[9]  
ROBA J, 1986, NEW ANTICONVULSANT D, P179
[10]  
ROWLAND M, 1995, CLIN PHARMACOKINET, P158